Investigators from Duke University Cancer Center Present Results from Precision Biologics Phase I Clinical Study Utilizing the Novel Antibody, NPC-1C (ensituximab) at American Association for Cancer Research’s 2013 Annual Symposium

Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers. Ensituximab is the first development stage antibody therapeutic discovered by Precision Biologics and part of a pipeline of antibodies that target specific cancers.